狼疮治疗市场－全球产业规模、份额、趋势、机会和预测，按治疗类型、给药途径、最终用户、地区和竞争细分，2020-2030 年预测

2024 年全球狼疮治疗市场价值为 71.2 亿美元，预计到 2030 年将达到 107.4 亿美元，复合年增长率为 7.09%。这一增长主要归因于全球红斑性狼疮盛行率的上升。红斑性狼疮是一种自体免疫疾病，患者免疫系统会攻击自身的组织和器官。此疾病引起的发炎可影响多个系统，包括关节、皮肤、肾臟、肺臟、心臟和大脑。红斑性狼疮的诊断通常很困难，因为其症状多样且与其他疾病重迭。在许多情况下，其特征性症状是脸颊上出现蝴蝶状皮疹。虽然有些人有遗传易感性，但感染、药物或日光照射也可能引发红斑性狼疮。根据美国红斑狼疮基金会的数据，全球有超过 500 万人患有红斑性狼疮，主要为 15 至 44 岁的人。

关键市场驱动因素

系统性红斑狼疮（SLE）全球盛行率上升

主要市场挑战

先进疗法成本高且低收入地区难以取得

主要市场趋势

个人化医疗在狼疮治疗的应用日益广泛

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：COVID-19 对全球狼疮治疗市场的影响

第六章：临床试验分析

第七章：全球狼疮治疗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依治疗类型（非类固醇抗发炎药、皮质类固醇、抗疟药、免疫抑制剂、生物製剂、其他）
  • 依给药途径（口服、静脉注射、皮下注射）
  • 按最终使用者（医院和诊所、门诊护理中心、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图
  • 按治疗类型
  • 依给药途径
  • 按最终用户
  • 按地区

第 8 章：北美狼疮治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第九章：欧洲狼疮治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 西班牙
  • 义大利

第十章：亚太狼疮治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第 11 章：南美洲狼疮治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 12 章：中东和非洲狼疮治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第十三章：市场动态

• 驱动程式
• 挑战

第 14 章：市场趋势与发展

• 产品发布
• 併购
• 最新动态

第 15 章：全球狼疮治疗市场：SWOT 分析

第 16 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 17 章：竞争格局

• GSK plc.
• Novartis AG
• AstraZeneca
• F. Hoffmann-La Roche Ltd
• Eli Lilly and Company
• ImmuPharma PLC
• Pfizer Inc.
• Sanofi SA
• Bristol-Myers Squibb Company
• Merck & Co., Inc.

第 18 章：策略建议

第19章调查会社について・免责事项

The Global Lupus Therapeutics Market was valued at USD 7.12 billion in 2024 and is projected to reach USD 10.74 billion by 2030, growing at a CAGR of 7.09%. This growth is largely attributed to the increasing global prevalence of lupus, an autoimmune condition in which the body's immune system attacks its own tissues and organs. The disease causes inflammation that can affect multiple systems, including the joints, skin, kidneys, lungs, heart, and brain. Diagnosing lupus is often difficult due to its diverse and overlapping symptoms with other conditions. A signature symptom in many cases is a butterfly-shaped rash across the cheeks. While some individuals are genetically predisposed, lupus can also be triggered by infections, medications, or exposure to sunlight. According to the Lupus Foundation of America, over five million people worldwide are affected by lupus, primarily those aged 15 to 44.

Key Market Drivers

Rising Global Prevalence of Systemic Lupus Erythematosus (SLE)

The growing prevalence of systemic lupus erythematosus (SLE), the most common and severe form of lupus, is a significant driver of the lupus therapeutics market. SLE is a chronic autoimmune condition where the immune system mistakenly attacks healthy tissues, resulting in inflammation and organ damage. This condition is especially prevalent among women of reproductive age and is disproportionately seen in African American, Hispanic, and Asian populations. The increasing awareness, improved diagnostic capabilities, and rising incidence of autoimmune disorders globally are collectively contributing to the market's expansion.

Key Market Challenges

High Cost of Advanced Therapies and Limited Access in Low-Income Regions

Despite advancements in treatment, the high cost of biologics and targeted lupus therapies presents a major challenge, particularly in low- and middle-income regions. These innovative drugs, although effective, are often unaffordable for many patients-even in high-income countries with insurance coverage. In regions with limited healthcare infrastructure and funding, access to these treatments remains restricted. The economic burden limits the use of advanced therapeutics, thereby widening the treatment gap. Additionally, constrained healthcare budgets and inadequate reimbursement policies further hinder the adoption of these high-cost medications.

Key Market Trends

Growing Adoption of Personalized Medicine in Lupus Treatment

An emerging trend in the lupus therapeutics market is the growing shift toward personalized medicine. This approach tailors treatment to an individual's genetic, molecular, and phenotypic characteristics. Personalized strategies are especially important in lupus, which is marked by variable symptoms, disease progression, and treatment responses.

Advances in genomics, proteomics, and immunophenotyping are enabling more precise patient stratification and treatment planning. For instance, researchers funded by the NIH have identified immune pathway signatures-such as type I interferon activity-that may help predict patient response to specific biologics. Clinical trials are now being designed with biomarker-driven enrollment to increase efficacy, reduce side effects, and streamline drug approvals.

These innovations are supported by government initiatives such as the FDA's Precision Medicine Initiative and the European Union's Horizon Europe framework, both of which prioritize the development of targeted therapies for complex diseases like lupus.

Key Market Players

• GSK plc.
• Novartis AG
• AstraZeneca
• F. Hoffmann-La Roche Ltd
• Eli Lilly and Company
• ImmuPharma PLC
• Pfizer Inc.
• Sanofi S.A.
• Bristol-Myers Squibb Company
• Merck & Co., Inc.

Report Scope:

In this report, the Global Lupus Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lupus Therapeutics Market, By Treatment Type:

• NSAIDs
• Corticosteroids
• Antimalarials
• Immunosuppressants
• Biologics
• Others

Lupus Therapeutics Market, By Route of Administration:

• Oral
• Intravenous
• Subcutaneous

Lupus Therapeutics Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Lupus Therapeutics Market, By Region:

• North America
  • United States
  • Mexico
  • Canada
• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Lupus Therapeutics Market.

Available Customizations:

Global Lupus Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Impact of COVID-19 on Global Lupus Therapeutics Market

6. Clinical Trial Analysis

• 6.1. Ongoing Clinical Trials
• 6.2. Completed Clinical Trials
• 6.3. Terminated Clinical Trials
• 6.4. Breakdown of Pipeline, By Development Phase
• 6.5. Breakdown of Pipeline, By Status
• 6.6. Breakdown of Pipeline, By Study Type
• 6.7. Breakdown of Pipeline, By Region
• 6.8. Clinical Trials Heat Map

7. Global Lupus Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment Type (NSAIDs, Corticosteroids, Antimalarials, Immunosuppressants, Biologics, Others)
  • 7.2.2. By Route of Administration (Oral, Intravenous, Subcutaneous)
  • 7.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 7.2.4. By Region
  • 7.2.5. By Company (2024)
• 7.3. Market Map
  • 7.3.1. By Treatment Type
  • 7.3.2. By Route of Administration
  • 7.3.3. By End User
  • 7.3.4. By Region

8. North America Lupus Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment Type
  • 8.2.2. By Route of Administration
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Lupus Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment Type
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By End User
  • 8.3.2. Canada Lupus Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment Type
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By End User
  • 8.3.3. Mexico Lupus Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment Type
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By End User

9. Europe Lupus Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment Type
  • 9.2.2. By Route of Administration
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Europe: Country Analysis
  • 9.3.1. Germany Lupus Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment Type
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By End User
  • 9.3.2. France Lupus Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment Type
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By End User
  • 9.3.3. United Kingdom Lupus Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment Type
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By End User
  • 9.3.4. Spain Lupus Therapeutics Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Treatment Type
      • 9.3.4.2.2. By Route of Administration
      • 9.3.4.2.3. By End User
  • 9.3.5. Italy Lupus Therapeutics Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Treatment Type
      • 9.3.5.2.2. By Route of Administration
      • 9.3.5.2.3. By End User

10. Asia-Pacific Lupus Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment Type
  • 10.2.2. By Route of Administration
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. Asia-Pacific: Country Analysis
  • 10.3.1. China Lupus Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment Type
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By End User
  • 10.3.2. India Lupus Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment Type
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By End User
  • 10.3.3. Japan Lupus Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment Type
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By End User
  • 10.3.4. South Korea Lupus Therapeutics Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Treatment Type
      • 10.3.4.2.2. By Route of Administration
      • 10.3.4.2.3. By End User
  • 10.3.5. Australia Lupus Therapeutics Market Outlook
    • 10.3.5.1. Market Size & Forecast
      • 10.3.5.1.1. By Value
    • 10.3.5.2. Market Share & Forecast
      • 10.3.5.2.1. By Treatment Type
      • 10.3.5.2.2. By Route of Administration
      • 10.3.5.2.3. By End User

11. South America Lupus Therapeutics Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Treatment Type
  • 11.2.2. By Route of Administration
  • 11.2.3. By End User
  • 11.2.4. By Country
• 11.3. South America: Country Analysis
  • 11.3.1. Brazil Lupus Therapeutics Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Treatment Type
      • 11.3.1.2.2. By Route of Administration
      • 11.3.1.2.3. By End User
  • 11.3.2. Argentina Lupus Therapeutics Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Treatment Type
      • 11.3.2.2.2. By Route of Administration
      • 11.3.2.2.3. By End User
  • 11.3.3. Colombia Lupus Therapeutics Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Treatment Type
      • 11.3.3.2.2. By Route of Administration
      • 11.3.3.2.3. By End User

12. Middle East and Africa Lupus Therapeutics Market Outlook

• 12.1. Market Size & Forecast
  • 12.1.1. By Value
• 12.2. Market Share & Forecast
  • 12.2.1. By Treatment Type
  • 12.2.2. By Route of Administration
  • 12.2.3. By End User
  • 12.2.4. By Country
• 12.3. MEA: Country Analysis
  • 12.3.1. South Africa Lupus Therapeutics Market Outlook
    • 12.3.1.1. Market Size & Forecast
      • 12.3.1.1.1. By Value
    • 12.3.1.2. Market Share & Forecast
      • 12.3.1.2.1. By Treatment Type
      • 12.3.1.2.2. By Route of Administration
      • 12.3.1.2.3. By End User
  • 12.3.2. Saudi Arabia Lupus Therapeutics Market Outlook
    • 12.3.2.1. Market Size & Forecast
      • 12.3.2.1.1. By Value
    • 12.3.2.2. Market Share & Forecast
      • 12.3.2.2.1. By Treatment Type
      • 12.3.2.2.2. By Route of Administration
      • 12.3.2.2.3. By End User
  • 12.3.3. UAE Lupus Therapeutics Market Outlook
    • 12.3.3.1. Market Size & Forecast
      • 12.3.3.1.1. By Value
    • 12.3.3.2. Market Share & Forecast
      • 12.3.3.2.1. By Treatment Type
      • 12.3.3.2.2. By Route of Administration
      • 12.3.3.2.3. By End User

13. Market Dynamics

• 13.1. Drivers
• 13.2. Challenges

14. Market Trends & Developments

• 14.1. Product Launches
• 14.2. Mergers & Acquisitions
• 14.3. Recent Developments

15. Global Lupus Therapeutics Market: SWOT Analysis

16. Porter's Five Forces Analysis

• 16.1. Competition in the Industry
• 16.2. Potential of New Entrants
• 16.3. Power of Suppliers
• 16.4. Power of Customers
• 16.5. Threat of Substitute Products

17. Competitive Landscape

• 17.1. GSK plc.
  • 17.1.1. Business Overview
  • 17.1.2. Company Snapshot
  • 17.1.3. Products & Services
  • 17.1.4. Financials (As Reported)
  • 17.1.5. Recent Developments
  • 17.1.6. Key Personnel Details
  • 17.1.7. SWOT Analysis
• 17.2. Novartis AG
• 17.3. AstraZeneca
• 17.4. F. Hoffmann-La Roche Ltd
• 17.5. Eli Lilly and Company
• 17.6. ImmuPharma PLC
• 17.7. Pfizer Inc.
• 17.8. Sanofi S.A.
• 17.9. Bristol-Myers Squibb Company
• 17.10. Merck & Co., Inc.

18. Strategic Recommendations

19. About Us & Disclaimer